Trypsin and chymotrypsin inhibitors in insects and gut leeches.

Current pharmaceutical design (2002-04-12)
Liliane Schoofs, Elke Clynen, Michel Salzet
ABSTRACT

The constant increase of life expectancy is associated with major ageing of developed populations. This indicates that the new century will have one of most epidemic progressions of cardiovascular, cancer and inflammatory diseases. The high challenge for medical research is to compress such morbidity. In these conditions, invertebrates have demonstrated to be truly useful models in drug discovery for such ageing diseases. The last decade, drug discovery in leeches has opened the gate of new molecules to treat emphysema, coagulation, inflammation, dermitis and cancer. Also other invertebrates such as insects, which evolved from the annelids, harvest potential interesting molecules, such as serine protease inhibitors that can be exploited by the medical industry.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
α-Chymotrypsin from bovine pancreas, Type II, lyophilized powder, ≥40 units/mg protein
Sigma-Aldrich
α-Chymotrypsin from bovine pancreas, (TLCK treated to inactivate residual tryspin activity), Type VII, essentially salt-free, lyophilized powder, ≥40 units/mg protein
Sigma-Aldrich
α-Chymotrypsin from bovine pancreas, Type I-S, essentially salt-free, lyophilized powder
Sigma-Aldrich
α-Chymotrypsin from bovine pancreas, ≥40 units/mg protein, vial of 5 mg
Sigma-Aldrich
α-Chymotrypsin from bovine pancreas, suitable for protein sequencing, salt-free, lyophilized powder
Chymotrypsin, BRP, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
α-Chymotrypsin from human pancreas, lyophilized powder